GLPwatch

[Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].

Nihon Rinsho · 2013

Last updated 2026-05-28

A study compared treatment options for elderly diabetic patients, finding that long-acting basal insulin or GLP-1 receptor agonists provided effective blood sugar control without serious low blood sugar events. The research notes that intensive therapy can reduce risks like heart disease and death but may increase the chance of hypoglycemia, which is linked to higher risks of heart attack, death, dementia, and fractures.

AI summary of the abstract below.

JournalNihon Rinsho, 2013
Citations1
Relative citation ratio0.04
NIH percentile4
Molecules
Conditions studied Type 2 Diabetes

Abstract

It has been established that diabetes is an independent risk factor for microvascular and macrovascular complications, and many studies indicate that diabetic subjects are at greater risk of dementia, depression and fracture. Risk reductions for microvascular, macrovascular and death were observed by intensive therapy using insulin or oral diabetic agents. But a history of hypoglycemia was increased myocardial infarction, mortality, dementia and fracture. So it is important that optimum glycemic control has to be achieved without hypoglycemia. Treatment with a long-acting basal insulin analogue or glucagon-like peptide-1(GLP-1) receptor agonist, provide effective glycemic control without serious hypoglycemia in elderly patients. Self-monitoring of blood glucose might be effective in improving glycemic control in elderly patients, and it is useful for the diagnosis of hypoglycemia.

Verbatim abstract via PubMed 24397172 ↗